Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss Q2 financial results and business updates.
Quiver AI Summary
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in oral antiviral therapies, announced a conference call scheduled for August 7, 2025, at 4:30 p.m. ET to discuss its financial results for Q2 2025 and provide a business update. Participants can join the call via a dedicated phone line or listen through a live audio webcast available on Atea's Investor Relations website. The company focuses on developing antiviral therapies for serious viral diseases, particularly targeting single-stranded RNA viruses, and is advancing its lead program involving a combination of bemnifosbuvir and ruzasvir for HCV treatment. A replay of the call will be accessible on the company's website shortly after the event.
Potential Positives
- Atea Pharmaceuticals is enhancing transparency and communication with investors by hosting a live conference call to discuss its financial results and business update.
- The company continues to advance its clinical pipeline focused on addressing serious viral diseases, indicating ongoing research and potential market presence in a critical area of healthcare.
Potential Negatives
- The press release emphasizes that all forward-looking statements are inherently uncertain, which may raise concerns among investors about the company's ability to meet its future expectations.
- The reliance on forward-looking statements may indicate potential risk and volatility in the company's future performance, which could negatively impact investor confidence.
- The lack of specific details on financial results and business updates in the announcement may suggest that the company's current situation could be less favorable than anticipated.
FAQ
When is Atea Pharmaceuticals' conference call?
Atea Pharmaceuticals will host its conference call on August 7, 2025, at 4:30 p.m. ET.
How can I access the audio webcast?
The audio webcast can be accessed under "Events and Presentations" on Atea's Investor Relations webpage.
What will be discussed during the conference call?
The conference call will cover financial results for Q2 2025 and provide a business update.
What is Atea Pharmaceuticals focusing on?
Atea is focused on developing oral antiviral therapies for serious viral infections, particularly HCV treatments.
Where can I find more information about Atea Pharmaceuticals?
More information can be found on Atea Pharmaceuticals' website at www.ateapharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVIR Hedge Fund Activity
We have seen 43 institutional investors add shares of $AVIR stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC removed 3,341,653 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $9,991,542
- FMR LLC removed 407,206 shares (-6.3%) from their portfolio in Q1 2025, for an estimated $1,217,545
- JPMORGAN CHASE & CO added 363,958 shares (+88.9%) to their portfolio in Q1 2025, for an estimated $1,088,234
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 272,732 shares (-69.8%) from their portfolio in Q1 2025, for an estimated $815,468
- DIMENSIONAL FUND ADVISORS LP added 206,256 shares (+21.1%) to their portfolio in Q1 2025, for an estimated $616,705
- CM MANAGEMENT, LLC added 200,000 shares (+66.7%) to their portfolio in Q1 2025, for an estimated $598,000
- CITADEL ADVISORS LLC removed 196,796 shares (-89.9%) from their portfolio in Q1 2025, for an estimated $588,420
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update.
To access the live conference call, participants may register here . The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com . To participate via telephone, please dial 1-877-300-8521 (U.S.) or 1-412-317-6026 (International) and use conference ID number 10201618. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com .
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
[email protected]
Joyce Allaire
LifeSci Advisors
[email protected]